1. Orally administrable peptides derived from egg yolk promote skeletal repair and ameliorate degenerative skeletal disorders in mouse models
- Author
-
Yoshiaki Kitaura, Utano Nakamura, Chihiro Awada, Motonori Yamaguchi, Mujo Kim, Yuki Ikeda, Yuki Matsuo, Takeshi Moriishi, Takashi Sawase, Ung-il Chung, Hironori Hojo, and Shinsuke Ohba
- Subjects
Biomaterials ,Biomedical Engineering ,Developmental Biology - Abstract
Aging, genetic mutations, and other pathological conditions cause impairment of skeletal growth and bone metabolism, which affect activities of daily living and quality of life in all life stages. Although several drugs have been used in clinical settings and new drugs have been developed for the treatment of skeletal degenerative disorders such as osteoporosis and genetic disorders such as osteogenesis imperfecta (OI), there is clear demand for development of new drugs, especially orally available anabolic drugs that are applicable for a wide range of skeletal disorders.To identify therapeutic candidates for skeletal disorders, peptide screening was performed. To validate the identified peptides, we performed a bone histomorphometric analysis with rat bone tissues andWe identified the egg yolk-derived functional peptide PF201. PF201 promotedD2 is likely to be a candidate for an orally available therapeutic for a range of skeletal disorders.
- Published
- 2022
- Full Text
- View/download PDF